<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825691</url>
  </required_header>
  <id_info>
    <org_study_id>ERG protein in cancer prostate</org_study_id>
    <nct_id>NCT04825691</nct_id>
  </id_info>
  <brief_title>ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features</brief_title>
  <official_title>ERG Protein Expression in Prostatic Acinar Adenocarcinoma and Its Correlation With Clinicopathological Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the ERG expression in prostatic acinar adenocarcinoma and its association with&#xD;
      clinicopathological features.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostatic cancer is one of the most common malignancies in males and is the second leading&#xD;
      cause of cancer-related deaths in males worldwide. The burden is expected to grow 1.7 million&#xD;
      new cases and 499,000 new deaths by 2030. Although the diagnosis of prostatic carcinoma can&#xD;
      usually be made on histological features, nowadays many immunohistochemical (IHC) markers are&#xD;
      used to distinguish it from benign mimickers as well as in predicting prognosis and&#xD;
      treatment. Out of these markers, Ets-related gene (ERG product) is a proto-oncogene which&#xD;
      participates in chromosomal translocations and is frequently over expressed in prostatic&#xD;
      carcinoma which harbors ERG-transmembrane protease, serine 2 fusion. ERG is a transcription&#xD;
      factor belonging to the erythroblast transformation-specific (ETS) family. It is involved in&#xD;
      many important cellular processes including differentiation, cell proliferation,&#xD;
      angiogenesis, cell migration, hematopoiesis, and apoptosis. This proto-oncogene is expressed&#xD;
      in the urogenital tract and hematopoietic cells. Gene fusions involving sequences of&#xD;
      transmembrane protease serine 2 (promoter of TMPRSS2) and protein coding sequences of ERG&#xD;
      result in over expression of ERG in prostatic tumors. This TMPRSS2-ERG fusion has been shown&#xD;
      to occur in 50-70% cases of prostatic acinar adenocarcinoma in different studies. Genetic&#xD;
      rearrangements were not identified in epithelial carcinomas until Tomlins et al. demonstrated&#xD;
      ERG gene fusions in prostatic carcinoma.The presence of this fusion is now believed to be a&#xD;
      critical event in the development of prostatic carcinoma.&#xD;
&#xD;
      TMPRSS2-ERG fusion results in constitutive expression of ERG oncoprotein resulting in&#xD;
      enhanced proliferation and invasive potential of prostatic cancer cells. Moreover,&#xD;
      TMPRSS2-ERG fusion gene product can be an important therapeutic target in prostatic cancer.&#xD;
      Immunohistochemical (IHC) expression of ERG oncoprotein may serve as a surrogate biomarker of&#xD;
      TMPRSS2-ERG fusion gene. Therefore in the present study we aimed to evaluate the ERG&#xD;
      expression in prostatic acinar adenocarcinoma and its association with clinicopathological&#xD;
      features.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 4, 2021</start_date>
  <completion_date type="Anticipated">May 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation the ERG expression in prostatic acinar adenocarcinoma</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between ERG expression with clinicopathological features.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>cases diagnosed as prostatic acinar adenocarcinoma</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Immunohistochemistry of prostate biopsy</intervention_name>
    <description>Sections of formalin fixed paraffin embedded tissue blocks will be stained with ERG oncoprotein. Antibody dilution, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions</description>
    <arm_group_label>cases diagnosed as prostatic acinar adenocarcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All cases diagnosed as prostatic acinar adenocarcinoma.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All cases diagnosed as prostatic acinar adenocarcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other types of prostatic cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </reference>
  <reference>
    <citation>Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol. 2009 Aug;6(8):429-39. doi: 10.1038/nrurol.2009.127. Review.</citation>
    <PMID>19657377</PMID>
  </reference>
  <reference>
    <citation>Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008 Jul;8(7):497-511. doi: 10.1038/nrc2402. Epub 2008 Jun 19. Review.</citation>
    <PMID>18563191</PMID>
  </reference>
  <reference>
    <citation>Berg KD, Vainer B, Thomsen FB, RÃ¸der MA, Gerds TA, Toft BG, Brasso K, Iversen P. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol. 2014 Nov;66(5):851-60. doi: 10.1016/j.eururo.2014.02.058. Epub 2014 Mar 7.</citation>
    <PMID>24630684</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Aya Mohammed Amin</investigator_full_name>
    <investigator_title>demonstrator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

